Latest Breaking News On - Relapsed refractory hodgkin lymphoma - Page 1 : comparemela.com

The FDA has granted fast track designation to the first-in-class innate cell engager AFM13 plus AlloNK for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Wolfgang fischerPhase 3 sequoiaFast track designationRelapsed refractory hodgkin lymphoma